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tatins
argeting Inflammation by
owering Low-Density Lipoprotein?*
. Murat Tuzcu, MD, FACC,
tephen J. Nicholls, MBBS, PHD, FRACP, FACC
leveland, Ohio
he pivotal role of low-density lipoprotein cholesterol
LDL-C) in the pathogenesis of atherosclerosis and its
schemic complications are well established. Epidemiologic
tudies demonstrate a linear relationship between levels of
DL-C and the prospective risk of cardiovascular events
1). In animal models, the administration of cholesterol
ncreases levels of LDL-C and promotes the formation of
esions (2). As a result, considerable effort has been devoted
o the development of therapeutic strategies that lower levels
f LDL-C to reduce cardiovascular risk. The finding that
ecreasing LDL-C with a range of agents in placebo-
ontrolled clinical trials is associated with lower event rates
3–8) has resulted in the incorporation of LDL-C reduction
s a cornerstone of therapeutic guidelines aimed at cardio-
ascular prevention. More recent evidence of incremental
linical benefit by reducing LDL-C to very low levels
9–11) provides a compelling argument for the use of
ntensive lipid lowering in the high-risk patient.
See page 2003
At the same time, increasing evidence supports the
oncept that atherosclerosis is a chronic inflammatory pro-
ess (12). The accumulation of inflammatory cells within
he arterial wall contributes to the formation of the mature
therosclerotic plaque. The plaque’s inflammatory compo-
ition influences its propensity to undergo fibrous cap
upture, the typical pathological trigger of acute ischemic
vents. This relationship between inflammatory activity and
laque rupture is highlighted by reports that systemic levels
f markers of inflammation, including C-reactive protein
CRP) (13) and myeloperoxidase (14), predict the prospec-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland,
hio. Dr. Tuzcu has received modest speaking honoraria from Pfizer, AstraZeneca, and
erck. Dr. Nicholls has received modest speaking honoraria from Pfizer, AstraZen-n
ca, and Merck Schering-Plough; consulting fees from AstraZeneca and Anthera
harmaceuticals; and research support from LipidSciences.ive risk of acute ischemic events in subjects with and
ithout established coronary artery disease. An extensive
earch is underway to identify new therapeutic strategies
hat modulate inflammation within the arterial wall.
Recent attention has focused on the possibility that
unctional properties, in addition to lowering levels of
DL-C, may contribute to the unequivocal clinical benefit
f statins. This concept has gained popularity, despite the
emonstration of a direct relationship between the degree of
DL-C lowering and clinical benefit in trials of statin
herapy (15). A number of lines of evidence support the
otential for clinically significant pleiotropic properties of
tatins. In a national registry of patients with acute myocar-
ial infarction, early initiation of statins is associated with
ncreased survival in the following year (16). Furthermore,
arly initiation of more potent statins results in an early
eduction in clinical event rates in randomized controlled
rials of patients with a recent acute coronary syndrome
9,17). The early separation of event curves observed in
hese reports is thought to precede the full extent of LDL-C
owering that ultimately is achieved with therapy. Statins
odify levels of other lipids and possess a number of in vitro
roperties that may contribute to a direct protective influ-
nce on the arterial wall in vivo (18). These pleiotropic
roperties appear to be derived from inhibition of isopre-
ylation of the Rho kinase pathway. In support of their
otential contribution to clinical efficacy, it has been ob-
erved that the greatest impact of high-dose atorvastatin on
oth clinical events (19) and atheroma progression (20) is
bserved in patients who achieved substantial lowering of
evels of both LDL-C and CRP, rather than just LDL-C
lone. This information complements data that suggest the
eneficial impact of high-dose atorvastatin on the rate of
laque progression cannot be completely accounted for by
uperior LDL-C lowering (21). These findings provide
urther support that anti-inflammatory properties of statins
re of potential significance in humans.
In the current issue of the Journal, Kinlay (22) uses novel
eta-analysis techniques to demonstrate a strong relation-
hip between changes in LDL-C and CRP in healthy and
table subjects with coronary artery disease (CAD) who
ere treated with LDL-lowering interventions in placebo-
ontrolled trials (22). A major limitation of interpreting
uch data in clinical trials involves the marked intra-
ndividual variability of CRP measurements. To control for
his variability, the current analysis was performed using
ean levels of LDL-C and CRP in each trial. Multivariate
nalysis in the range of LDL-C reduction typically seen
ith statins revealed that almost all of the observed change
n CRP was related to decreasing levels of LDL-C. These
ndings support a previous meta-analysis that demonstrated
hat nearly all of the clinical benefit in lipid-lowering trials
an be attributed to the degree of LDL-C reduction (23). In
ddition, they provide important insights into the mecha-
ism that translates LDL-C lowering to clinical benefit.
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2011JACC Vol. 49, No. 20, 2007 Tuzcu and Nicholls
May 22, 2007:2010–2 Editorial CommentAlthough these findings provide further impetus for the
oncept that lowering levels of LDL-C play an important
ole in reducing cardiovascular risk, a number of important
aveats should be noted. More than 80% of the trials in the
eta-analysis involved administration of a statin, which
esulted in more effective lowering of LDL-C and CRP
han nonstatin interventions. Assessing the impact of statins
n CRP beyond their LDL effect would have been more
obust had this study included more nonstatin trials. The
urrent analysis excluded clinical trials performed in patients
ith unstable ischemic syndromes. Given the association of
laque inflammation with its propensity to rupture, it is
ossible that potential anti-inflammatory properties of
tatins may play a more important role in this clinical
etting. Furthermore, it has been reported that CRP levels
ypically are much greater in the setting of acute coronary
yndromes than in the patients studied in the current
nalysis (24). This distinction is highlighted by the finding
f an early separation of event curves only in statin trials of
atients with unstable ischemic syndromes. In contrast,
linical benefit in trials of patients with stable CAD is
ypically not observed for more than 12 months. This early
indow of protection during which there is a lack of a
elationship between LDL-C reduction and clinical benefit
uggests that pleiotropic properties of statins may contribute
o their efficacy, which is highlighted by the observation that
ubstantial lowering of CRP, in addition to LDL-C, results
n the greatest clinical benefit of high-dose atorvastatin in
atients with an acute coronary syndrome (19).
The primary analysis by Kinlay (22) excluded nonplacebo-
ontrolled trials, which results in the omission of recent
rials that involved a comparison of low- and high-dose
tatin therapy. It was of interest to note that in further
nalysis of trials that directly compared statin doses, a
imilar relationship was demonstrated. However, it should
e noted that given the increasing enrollment of patients
ith an acute ischemic syndrome in these clinical trials, the
ajority of studies were not included. It therefore remains
o be fully established whether the current findings do occur
ith high-dose statin therapy in patients with unstable
ymptoms. This information has important implications
iven the increasing use of high-dose statin therapy in
igh-risk patients with established CAD. In fact, compar-
son of the A to Z (Aggrastat to Zocor) and PROVE IT
Pravastatin or Atorvastatin Evaluation and Infection Ther-
py) studies provides preliminary evidence to suggest that
nti-inflammatory properties of intensive statin therapy may
e of clinical importance. The finding of an early separation
n event curves only in PROVE IT was accompanied by a
maller difference in LDL-C but greater difference in CRP
etween the intensive and moderate statin arms (25).
The current findings report the relationship between
hanges in LDL-C and CRP, not inflammatory events.
hey do not provide the opportunity to distinguish between
ausation or association. Although the current findings
uggest that, in patients with stable CAD, lowering CRP (ith lipid-lowering interventions appears to be primarily
riven by lowering levels of LDL-C, it remains possible that
hese interventions do have a significant and independent
ffect on inflammatory pathways. C-reactive protein is a
elatively nonspecific marker of inflammatory activity, and
onsiderable debate has focused on whether it plays a direct
ole in atherosclerosis. Reports that recombinant CRP
timulates a number of pathological pathways implicated in
therogenesis are confounded by its potential contamination
ith endotoxin (26). It would be of interest to perform the
urrent analysis with additional inflammatory markers that
nvolve factors with well-established pathological roles in
theroma formation and rupture. This analysis would pro-
ide further insight into the possibility that lipid-lowering
nterventions possess anti-inflammatory properties. In ad-
ition, the current analysis does not investigate the impact
f these lipid-modifying interventions on other lipid param-
ters, such as high-density lipoprotein cholesterol, which
ay itself possess anti-inflammatory properties, or lipopro-
ein particle size. Given the increasing importance of
ipoprotein functionality and their influence on the arterial
all, it is imperative to gain further insight into how
ipid-modifying interventions modulate both the quantity
nd quality of circulating lipid particles.
What are the implications of the findings of Kinlay (22)
or the management of patients at an increased risk of
ardiovascular events? Lowering levels of LDL-C remains a
entral component of all strategies designed to reduce
ardiovascular risk, and this strategy is likely to have a
econdary benefit in modifying inflammatory activity within
he arterial wall. This strategy also is consistent with the
bjective of the JUPITER (Justification for the Use of
tatins in Primary prevention: an Intervention Trial Evalu-
ting Rosuvastatin) study, which aims to determine the
linical utility of triage of high-risk patients, on the basis of
ncreased CRP levels, to lipid lowering with a statin (27). It
ill be of interest to investigate the findings of such a
trategy on the results of the current analysis. Development
f therapeutic strategies that inhibit cholesterol synthesis
ut preserve isoprenylation of the Rho kinase pathway
hould provide further insight into the relative contribution
f LDL-C and CRP lowering to clinical benefit. Regard-
ess, it has been well established that use of lipid-lowering
nterventions are associated with a substantial residual risk
f clinical events.
It should be emphasized that the findings of this mech-
nistic study do not diminish the potential link between
nflammation and associated biomarkers in atherosclerosis
nd cardiovascular risk prediction. In particular, the cur-
ent observations in no way detract from the concept that
he patient with low levels of LDL-C but an elevated
RP may be at greater risk than the patient with low
DL-C and low CRP. Accordingly, there is an ongoing
eed to develop new therapies to complement existing
revention strategies. The findings of the study by Kinlay
22) provide further impetus to continue to strive to
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Editorial Comment May 22, 2007:2010–2iscover new therapies that act to directly modify patho-
ogical events in the arterial wall.
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